| Stage | IQV | % of rev | MEDP | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $4.4B | 100.00% | $716M | 100.00% | IQV ×6.18 |
| Gross profit | $1.5B | 33.83% | $716M | 100.00% | MEDP +66.2pp |
| Operating income | $572M | 12.92% | $166M | 23.12% | MEDP +10.2pp |
| Pre-tax income | $386M | 8.72% | $171M | 23.87% | MEDP +15.2pp |
| Net income | $352M | 7.95% | $137M | 19.20% | MEDP +11.2pp |
| Stage | IQV | MEDP | Gap · A − B |
|---|---|---|---|
| Revenue | $4.4B100.00% | $716M100.00% | IQV ×6.18 |
| Gross profit | 33.83%$1.5B | 100.00%$716M | MEDP +66.2pp |
| Operating income | 12.92%$572M | 23.12%$166M | MEDP +10.2pp |
| Pre-tax income | 8.72%$386M | 23.87%$171M | MEDP +15.2pp |
| Net income |
| 7.95%$352M |
| 19.20%$137M |
| MEDP +11.2pp |